This retrospective chart review looked at six PSC patients who had active ulcerative colitis and who had failed standard treatments including mesalamine, immunomodulators, and biologics. Within six weeks of starting oral vancomycin, all six patients found clinical remission and maintained remission for two years of follow-up. They also had improved liver numbers. Read the full […]
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium
In this retrospective study, the Paediatric PSC Consortium compared the health of patients with PSC and IBD who had taken oral vancomycin (OV) to PSC-IBD patients who had not taken OV. Out of 113 patients with PSC-IBD, 70 were treated with OV, and they had a better chance of their IBD going into remission compared […]
Oral Vancomycin Induces Sustained Deep Remission in Adult Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis
This paper is a collection of three brief case reports that describes the effect of oral vancomycin treatment in three patients with UC and PSC. All three patients achieved clinical remission and mucosal healing with vancomycin. The patients took 500 mg twice a day. Maintenance treatment with oral vancomycin led to sustained clinical and endoscopic […]
Read and Download All Research Articles
2024 2023 2022 2021 2020 2019 Cancer Risk in Primary Sclerosing Cholangitis: Epidemiology, Prevention, and Surveillance Strategies Or read the article online. 2018 2017 2016 2013 2008